RBC Capital analyst Ben Hendrix raised the firm’s price target on CVS Health (CVS) to $74 from $58 and keeps an Outperform rating on the shares. The company is past its earnings trough with management setting 2025 guidance ahead of expectations while also expressing confidence in its long-term Medicare Advantage – MA – margin recovery, the analyst tells investors in a research note. The MA utilization appears to have stabilized, which, alongside disciplined pricing, could drive upside to consensus estimates in the out years, RBC adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health price target raised to $70 from $66 at Deutsche Bank
- CVS Health Corp’s Mixed Earnings Call Highlights Growth and Challenges
- CVS Health price target raised to $76 from $60 at Truist
- Target downgraded, Cisco upgraded: Wall Street’s top analyst calls
- CVS Health price target raised to $75 from $63 at BofA